arrow
F

Fausto Castagnetti

university of bologna
H指数:45
被引数:7,891

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study

年龄和性别对慢性髓性白血病患者在一线治疗中分子反应的影响:一项意大利CML网络队列研究

2026-04-180
OAAI
Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

慢性髓性白血病急变期预后评分系统的开发

Leukemia
IF13.4
2026-02-190
OA
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study
2026-01-110
OA
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较,包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists

GIMEMA关于慢性髓性白血病患者在第三线及以后治疗管理情况的调查:来自意大利血液学家的见解

2025-11-180
OAAI
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial

健康相关生活质量对慢性髓性白血病患者早期分子应答的预测价值:GIMEMA-SUSTRENIM试验分析

2025-08-270
OA
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability

SETD2功能缺失是进展期慢性髓性白血病中的常见事件,并导致基因组不稳定。

2025-04-240
OAAI
Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

酪氨酸激酶抑制剂在慢性髓性白血病中的停药:意大利673例患者的观察性研究

BLOOD
IF23.1
2024-11-050
PRE
CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or < 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

慢性粒细胞白血病患者在12个月时未达到BCR::ABL1 ≤ 1%(主要分子缓解,MMR)或在24个月时未达到BCR::ABL1 < 0.1%,其生存率显著较差,但并非由于CML相关死亡:一项意大利真实世界观察性研究的数据

BLOOD
IF23.1
2024-11-050
PRE
ASXLI Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

ASXLI突变在诊断时并未影响慢性期(CP)慢性粒细胞白血病(CML)患者(pts)在SUSTRENIM临床试验中接受尼洛替尼(NIL)一线治疗或伊马替尼(IM)联合早期切换至尼洛替尼(NIL)(在无最佳应答情况下)的分子应答深度(MR)及无治疗缓解(TFR)资格。

BLOOD
IF23.1
2024-11-051
PRE
Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

停用一线治疗后慢性粒细胞白血病患者中的无治疗缓解

BLOOD
IF23.1
2024-11-050
PRE
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
LEUKEMIA
IF13.4
2024-03-284
OAAI
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
2023-11-286
OAAI
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
CANCER
IF5.1
2023-10-063
OAAI